SCHEMBL4073751

SCHEMBL4073751

Cc1cc(C)c2[nH]c(=O)c(CN(Cc3ccc4c(c3)OCO4)C(=O)Nc3ccc(Cl)cc3)cc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.65
MAPT P10636 5/20 0.65
USP2 O75604 4/20 0.65
HPGD P15428 3/20 0.65
POLB P06746 3/20 0.65
LMNA P02545 2/20 0.65
FYN P06241 1/20 0.59
ALDH1A1 P00352 5/20 0.56
NPSR1 Q6W5P4 3/20 0.56
MAPK1 P28482 4/20 0.53
ALOX15 P16050 3/20 0.51
ALOX12 P18054 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TSHR P16473 4/20 0.51
GAA P10253 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
HSD17B10 Q99714 3/20 0.51
HTT P42858 2/20 0.51
CASP1 P29466 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457669 0.92 KDM4E (0.65) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4076652 0.90 KDM4E (0.64) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4080208 0.85 KDM4E (0.56) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL5454347 0.85 KDM4E (0.57) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4070133 0.85 KDM4E (0.55) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4073864 0.84 KDM4E (0.55) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4079782 0.84 KDM4E (0.56) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL5448947 0.83 KDM4E (0.66) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4073672 0.83 ALDH1A1 (0.58) KDM4EMAPTUSP2HPGDPOLB
SCHEMBL4079794 0.83 ALDH1A1 (0.53) KDM4EMAPTUSP2HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885MAPT 4297/4885USP2 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.